CD3: Difference between revisions
From haematologyetc.co.uk
No edit summary |
No edit summary |
||
Line 27: | Line 27: | ||
* Natural Killer cell lymphoproliferative disorders do not express a conventional TCR so CD3 is not expressed. | * Natural Killer cell lymphoproliferative disorders do not express a conventional TCR so CD3 is not expressed. | ||
* B cells will not express CD3, and aberrant expression in AML is rare (in contrast to other T cell marker such as CD2 or CD7). | |||
Line 33: | Line 35: | ||
<span style="color:navy">'''Other relevant information:'''</span> | <span style="color:navy">'''Other relevant information:'''</span> | ||
Line 87: | Line 88: | ||
! ATLL !! CTCL/Sezary !! T-PLL !! T-LGL !! NK-LGL | ! ATLL !! CTCL/Sezary !! T-PLL !! T-LGL !! NK-LGL | ||
|- | |- | ||
|style="width: 14.25%; background: #004466; color:white"|80-100% | |style="width: 14.25%; background: #004466; color:white"|80-100% Wk | ||
|style="width: 14.25%; background: #004466; color:white"|80-100% | |style="width: 14.25%; background: #004466; color:white"|80-100% Wk | ||
|style="width: 14.25%; background: #004466; color:white"|80-100% | |style="width: 14.25%; background: #004466; color:white"|80-100% Strg | ||
|style="width: 14.25%; background: #004466; color:white"|80-100% | |style="width: 14.25%; background: #004466; color:white"|80-100% Strg | ||
|style="width: 14.25%; background: #E6FAFF; color:black"|<5% | |style="width: 14.25%; background: #E6FAFF; color:black"|<5% | ||
|- | |- | ||
|} | |} | ||
<span style="font-size:90%">'''Notes:''' | <span style="font-size:90%">'''Notes:''' The level of CD3 expression is increased (compared to normal T cells) in T-PLL and T-LGL, and is decreased in ATTL, Sézary syndrome and ATLL. </span> | ||
---- | ---- |
Revision as of 21:37, 30 April 2023
- Summary
- CD3 is a reliable marker of T cell lineage. Loss of expression is rare in T cell malignancies, and aberrant expression by other lineages is very infrequent.
- Surface CD3 is acquired during thymic maturation, but is preceded by expression in cytoplams, smaking cytoplasmic CD3 is very useful in the diagnosis of acute T cell leukaemia.
- On more mature neoplasms CD3 will be detected on the cell surface.
Normal expression and function
CD3 is not a single molecule, rather it is a multi-molecular complex (two epsilon (ε) chains, a gamma (γ) chain, a delta (δ) chain and a zeta (ζ) chain) that play a pivitol role in assembling and activating the T cell receptor. It is first expressed in the cytoplasm becoming expressed on as they mature. As an essential TCR component it is expressed almost exclusively by mature T cells.
Diagnostic role
- In T cell Acute Lymphocytic Leukaemia CD3 expression is mainly cytoplasmic (cyCD3). Surface (sCD3) is variably expressed in more mature forms of T-ALL.
- In mature T cell neoplasms sCD3 is found on T-prolymphocytic leukaemia, Sézary syndrome, Adult T cell leukaemia/lymphoma (ATLL), Angioimmunoblastic T cell lymphoma (AITL), T-Large granular lymphocytic leukaemia (T-LGL) and Hepatosplenic T-cell lymphoma.
- Natural Killer cell lymphoproliferative disorders do not express a conventional TCR so CD3 is not expressed.
- B cells will not express CD3, and aberrant expression in AML is rare (in contrast to other T cell marker such as CD2 or CD7).
Other relevant information:
SUMMARY TABLES
Expression in primitive cell types | ||||||
---|---|---|---|---|---|---|
AML | B ALL | Burkitt | T ALL | ETP ALL (i) | MPAL i | Hgns i |
<5% | <5% | <5% | 80-100% c/sCD3 | 80-100% cCD3 | 20-40% c/sCD3 | <5% |
Notes: xxxxx
CD13 expression: mature B cell neoplasms | |||||||
---|---|---|---|---|---|---|---|
CLL | MCL | FL | MZL | HCL | DLBCL | LPL | PCL |
<5% | <5% | <5% | <5% | <5% | <5% | <5% | <5% |
Notes: xxxxx
Expression in mature T cell neoplasms* | ||||||
---|---|---|---|---|---|---|
ATLL | CTCL/Sezary | T-PLL | T-LGL | NK-LGL | ||
80-100% Wk | 80-100% Wk | 80-100% Strg | 80-100% Strg | <5% |
Notes: The level of CD3 expression is increased (compared to normal T cells) in T-PLL and T-LGL, and is decreased in ATTL, Sézary syndrome and ATLL.